Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Second Study of Expanded Access Patients Treated with PV-10 for In-Transit Melanoma Published in Journal of Surgical Oncology
Thursday April 19, 2018
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, today announced that the Journal of Surgical Oncology ("JSO") had published results from an investigator-led, single-center study of patients with in-transit melanoma who received intralesional PV-10 under expanded access. The JSO article detailed the experience of investigators at the Princess Alexandra Hospital in Brisbane, Australia treating 45 patients with almost exclusively Stage III disease from 2008 to 2015.
The current article may be accessed via the JSO's website at https://onlinelibrary.wiley.com/doi/10.1002/jso.24921.1
Patients and Key Results
Baseline characteristics: 60% men; median age of 76 years (range 51-90); 96% Stage IIIIB-C; median of 2 prior directed locoregional therapies
Median of 6 lesions treated with PV-10 (range 1-31); median of 2 treatments with PV-10 (range 1-4)
Per patient best overall response: 42% complete response, 44% partial response, and 7% stable disease
22% durable response rate (an objective response lasting more than 6 months from the time of first PV-10 treatment)
Median overall survival of 25 months from the first PV-10 treatment; 12-, 24-, 36-, and 48-month overall survival rates of 90%, 85%, 68% and 65%, respectively, from the time of first PV-10 treatment
At least one Grade 1 or 2 treatment-associated adverse event per patient; a total of three treatment-associated Grade 3 adverse events (treatment site ulceration, cellulitis, and photosensitivity reaction)
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "These data are consistent with prior analyses of patients treated with PV-10 in monotherapy settings as well as the clinical expectations underlying the design of our ongoing pivotal Phase 3 trial. This and other expanded access work, together with our historical and ongoing melanoma clinical trials, strongly support the continued relevance of PV-10 for the treatment of melanoma."
About PV-10
Provectus' lead investigational cancer drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.
About In-Transit Melanoma
According to the current NCCN Guidelines for Patients®, Melanoma, Version 1.2016 2, Stage III in-transit melanoma is when cancer cells have spread into lymph vessels near the first tumor but not into nearby lymph nodes. Melanoma that has spread to a small area of skin near the first tumor is called satellite metastasis. Non-metastatic recurrence is melanoma that has come back after treatment but has not spread to distant parts of the body. According to the NCCN Guidelines for Melanoma, version 1.2018 3, under Treatment for Stage III In-transit Disease, " the tumor burden, time course of appearance, and duration of in-transit disease is variable. In some patients, in-transit lesions remain confined to a region of the body for many years. This may occur in isolation or in combination with other sites of metastatic disease. A major concern in patients in which in-transit disease occurs in isolation is the high probability of subsequent development of visceral metastasis."
About Our Phase 3 Trial of PV-10 as a Monotherapy for Stage III-VI M1a Melanoma
For patients with locally advanced cutaneous melanoma, Provectus is evaluating IL PV-10 versus chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy in an international, multi-center, pivotal Phase 3 trial (NCT02288897). In-transit, satellite and locally recurrent melanoma patients (Stage IIIB, IIIC or IV M1a) with at least one injectable lesion who are not candidates for treatment with either a checkpoint inhibitor or targeted therapy (with BRAF or combined BRAF/MEK inhibitors) are eligible. The trial's primary endpoint is progression-free survival (assessed via RECIST 1.1 every 12 weeks up to 18 months); complete response rate and overall survival are key secondary endpoints. More information about this Phase 3 trial is available via ClinicalTrials.gov:
https://www.clinicaltrials.gov/ct2/show/NCT02288897
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).
References:
1. The first study of expanded access patients treated with PV-10 for in-transit melanoma was authored by investigators at Peter MacCallum Cancer Centre in Melbourne, Australia: Lippey at al., Intralesional PV-10 for in-transit melanoma - a single-center experience. J Surg Oncol. 2016;114: 380–384. https://onlinelibrary.wiley.com/doi/10.1002/jso.24311. Accessed March 15, 2018.
2. National Comprehensive Cancer Network. Patients, Melanoma (Version 1.2016). https://www.nccn.org/patients/guidelines/mpm/files/assets/common/downloads/files/mpm.pdf. Accessed March 15, 2018.
3. National Comprehensive Cancer Network. Melanoma (Version 1.2018). https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (registration required). Accessed March 15, 2018.
The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180419-1 on the Provectus website.
$PVCT, Provectus News
Provectus Biopharmaceuticals Expands Global Patent Portfolio for Cancer Combination Therapy
Thursday April 19, 2018
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers, today announced that the Journal of Surgical Oncology ("JSO") had published results from an investigator-led, single-center study of patients with in-transit melanoma who received intralesional PV-10 under expanded access. The JSO article detailed the experience of investigators at the Princess Alexandra Hospital in Brisbane, Australia treating 45 patients with almost exclusively Stage III disease from 2008 to 2015.
The current article may be accessed via the JSO's website at https://onlinelibrary.wiley.com/doi/10.1002/jso.24921.1
Patients and Key Results
Baseline characteristics: 60% men; median age of 76 years (range 51-90); 96% Stage IIIIB-C; median of 2 prior directed locoregional therapies
Median of 6 lesions treated with PV-10 (range 1-31); median of 2 treatments with PV-10 (range 1-4)
Per patient best overall response: 42% complete response, 44% partial response, and 7% stable disease
22% durable response rate (an objective response lasting more than 6 months from the time of first PV-10 treatment)
Median overall survival of 25 months from the first PV-10 treatment; 12-, 24-, 36-, and 48-month overall survival rates of 90%, 85%, 68% and 65%, respectively, from the time of first PV-10 treatment
At least one Grade 1 or 2 treatment-associated adverse event per patient; a total of three treatment-associated Grade 3 adverse events (treatment site ulceration, cellulitis, and photosensitivity reaction)
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "These data are consistent with prior analyses of patients treated with PV-10 in monotherapy settings as well as the clinical expectations underlying the design of our ongoing pivotal Phase 3 trial. This and other expanded access work, together with our historical and ongoing melanoma clinical trials, strongly support the continued relevance of PV-10 for the treatment of melanoma."
About PV-10
Provectus' lead investigational cancer drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.
About In-Transit Melanoma
According to the current NCCN Guidelines for Patients®, Melanoma, Version 1.2016 2, Stage III in-transit melanoma is when cancer cells have spread into lymph vessels near the first tumor but not into nearby lymph nodes. Melanoma that has spread to a small area of skin near the first tumor is called satellite metastasis. Non-metastatic recurrence is melanoma that has come back after treatment but has not spread to distant parts of the body. According to the NCCN Guidelines for Melanoma, version 1.2018 3, under Treatment for Stage III In-transit Disease, " the tumor burden, time course of appearance, and duration of in-transit disease is variable. In some patients, in-transit lesions remain confined to a region of the body for many years. This may occur in isolation or in combination with other sites of metastatic disease. A major concern in patients in which in-transit disease occurs in isolation is the high probability of subsequent development of visceral metastasis."
About Our Phase 3 Trial of PV-10 as a Monotherapy for Stage III-VI M1a Melanoma
For patients with locally advanced cutaneous melanoma, Provectus is evaluating IL PV-10 versus chemotherapy (dacarbazine or temozolomide) or oncolytic viral therapy in an international, multi-center, pivotal Phase 3 trial (NCT02288897). In-transit, satellite and locally recurrent melanoma patients (Stage IIIB, IIIC or IV M1a) with at least one injectable lesion who are not candidates for treatment with either a checkpoint inhibitor or targeted therapy (with BRAF or combined BRAF/MEK inhibitors) are eligible. The trial's primary endpoint is progression-free survival (assessed via RECIST 1.1 every 12 weeks up to 18 months); complete response rate and overall survival are key secondary endpoints. More information about this Phase 3 trial is available via ClinicalTrials.gov:
https://www.clinicaltrials.gov/ct2/show/NCT02288897
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).
References:
1. The first study of expanded access patients treated with PV-10 for in-transit melanoma was authored by investigators at Peter MacCallum Cancer Centre in Melbourne, Australia: Lippey at al., Intralesional PV-10 for in-transit melanoma - a single-center experience. J Surg Oncol. 2016;114: 380–384. https://onlinelibrary.wiley.com/doi/10.1002/jso.24311. Accessed March 15, 2018.
2. National Comprehensive Cancer Network. Patients, Melanoma (Version 1.2016). https://www.nccn.org/patients/guidelines/mpm/files/assets/common/downloads/files/mpm.pdf. Accessed March 15, 2018.
3. National Comprehensive Cancer Network. Melanoma (Version 1.2018). https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (registration required). Accessed March 15, 2018.
The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180419-1 on the Provectus website.
The Approved Monsanto-Bayer Merger Could Spell Disaster For A Budding Cannabis Industry
Probably not the main reason, but a nice perk for these "wonderful people", sad.
https://www.naturalblaze.com/2018/04/the-approved-monsanto-bayer-merger-could-spell-disaster-for-a-budding-cannabis-industry.html
After selling off enough assets to win anti-trust approval, the Department of Justice (DOJ) has approved a mega-merger between Monsanto and Bayer, two of the world’s leading chemical/biotech companies. Although polling has shown that over 90 percent of farmers are concerned about the merger, the DOJ and European Commission have given the green light for what is being called a “Merger from Hell.”
Not only will this merger result in less competition and reduced leverage for farmers, but it also paves the way for a de facto corporate takeover of the emerging cannabis industry through patent-pending genetically modified seeds.
“The Justice Department’s rubber stamping of these three seed mega-mergers transforms the already concentrated agrichemical and seed market, effectively reducing the number of competitors from six to three.” ~Wenonah Hauter, executive director of Food & Water Watch
As reported last year by Big Buds magazine, Monsanto and Scotts Miracle-Gro have a business partnership which expands far into the realms of cannabis production. Several companies which produce lighting and hydroponics for indoor cannabis growing have reported attempted buy-outs by Hawthorne, a front company for Monsanto, and Scotts CEO Jim Hagedorn has stated his interest in investing “half a billion in the pot business.”
If the newly merged Bayer/Monsanto corporation gets a patent on the cannabis plant, it could wreak havoc on an otherwise growing industry which is rapidly expanding the economies of states where it has been legalized, creating numerous new jobs in a highly desired field.
This $62.5 billion-dollar merger has unsurprisingly resulted in a 4.7% jump in the stock market for Bayer and a 6.2% jump for Monsanto, as large corporate mergers usually indicate growth. However, news of this merger and the interest that the company has in cannabis has caused a considerable public upset and criticism by non-profits and environmental interest groups.
“The Department of Justice has decided that corporate profits matter more than the interests [of] consumers and farmers. This decision will massively increase the power of major agrichemical companies that already have a stranglehold on our food system.” ~Jason Davidson, food and technology campaign associate with Friends of the Earth
As Bayer and Monsanto move closer to becoming one, the likelihood of genetically engineered cannabis is rapidly increasing. Some of the most common and widely-debunked selling points of GMO crops are increased yields, greater nutritional value, and easier maintenance. Similarly, if GMO marijuana was on the table they could tout some of the same points, only slightly changed to indicate increased potency and denser buds.
However, the onset of GMOs has also aided in a lessening of genetic diversity for crops, which could spread to cannabis as well.
“There used to be hundreds of commercial varieties of apples. Today there are less than two dozen. The United Nations warns that the diversity of cultivated crops declined by 75% during the 20th Century and a third of today’s crop diversity could disappear by 2050. The global plant breeding market is dominated by multinationals like Monsanto. They’re stealing Nature from us.” – Michael Straumietis, founder and owner of hydroponics nutrients company Advanced Nutrients
Instead of creating more diversity and cheaper cannabis, this new megacompany could effectively use the power to force growers into lessening their output and growing only the strains which Monsanto/Bayer wants to produce, regardless of any negative side effects. Ultimately, this is far too much power to grant to one multinational corporation.
The cannabis industry should continue to expand and contribute to the growing economy, and not come under the heels of large corporations who seek to dominate yet another large and important industry.
Thanks buddy, Quite here!
No, email me.fitzkarz@yahoo.com
fitz, I got some info I'd like to send you. Can I still PM you at iHang?
The Lithium Sector Surge Is Poised to Ignite a Deals Bonanza
Graphs in link
https://www.bloomberg.com/news/articles/2018-03-20/the-lithium-sector-surge-is-poised-to-ignite-a-bonanza-for-deals
$DJIFF Paid group member with moring conference calls says his group is looking at it, thinks lithium could come back
http://stockcharts.com/h-sc/ui?s=DJIFF&p=D&yr=5&mn=0&dy=0&id=p07713333947
$RIBT Continental Grain bought another 1,100,000 shares last week. I guess they own 22% now, and can NOT buy the company.
https://ih.advfn.com/p.php?pid=nmona&article=77026127
$SLDB Volume2.04m
closed @ 9.57 +0.25( 2.68%)
Open9.45
Day's Low9.01
Day's High9.79
52 Wk Low8.95
52 Wk High33.74
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#CvmKkdwUwGU8sdw4.99
Solid Biosciences Inc.
(NASDAQ : $SLDB)
9.32-16.99( -64.58%)
SLDB PreMarket: $9.40 +0.08 (0.86%) as of 8:40
AM
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#g7YRdciJZxCejjBf.99
$KCPC McAfee play, dipping right now; worth putting on watch.
Put on watch, Solid Biosciences Inc.
(NASDAQ : SLDB)
26.31
-0.13
( -0.49%
)
SLDB PreMarket: $10.75 -15.56 (-59.14%) as of 8:28
AM
Read more at http://thestockmarketwatch.com/stock/?stock=SLDB#YAcqopJ8LBBu6Skw.99
Feeding the Future: The Changing Landscapes of Food and Agriculture
Interesting video for me about food and water. A panel of 5 chaired by the CEO of Continental Grain, with a Monsanto man, Pepsi man, and Israeli company water mann and for me, the Ceo and founder of Impossible Foods. A statement by The CG man caught my attention art the 1:10 mark>>>
Paul Fribourg, Chairman and CEO, Continental Grain Company "We used to be the largest cattle feeder in the United States. When we heard Pat(CEO Impossible Foods} was going to replace real beef we sold our cattle feeding business and invested in Pat's company"
So, meat made from grains and chemicals is probably on the horizon. The MON man said in coming years the world will need 40% more grains, so that is bullish for RJA, MON, DE, etc.
So much for that, now my stock RIBT, a big loser for me, but they are into rice bran protein and meat filler. A senion VP of CG is on the RIBT board. 3 months after this video came out, CG bought 16% of RIBT. OK, only under $3M, not much in the scheme of things for a monster like CG. But........................
http://stockcharts.com/h-sc/ui?s=RIBT&p=D&yr=1&mn=0&dy=0&id=p72322183997
Video>>>>>
https://www.youtube.com/watch?v=pNG1Q7d7uIw
Hi buddy, Hope all is well. I'm still in $BLDV and $SHMN
Hope you're doing well, fitz! I keep promising to be active here but life comes at you fast. Hopefully I'll be able to find some good dip and rip opportunities to contribute to the forum.
$XXII has been a promising stock to flip ($2.60-$2.90), I have $DDD on watch (earnings tomorrow), $INFN has been tearing it up, and $GRUB has been doing well lately too.
$BLDV worth keeping on watch, though it's been pretty dead in the water as of late. (all of these are OTCs)
Filing coming out on Thursday hopefully, but the company is diluting at the moment
$SFOR taking off again, definitely worth keeping on watch at least.
$SRAX Publishes White Paper Outlining Details of Blockchain Technology BIG Platform
Snippet:
SRAX plans to be the first public company to deliver a transparent data management and distribution system through a secure blockchain platform, token reward, and open source governance structure.
https://www.prnewswire.com/news-releases/srax-publishes-white-paper-outlining-details-of-blockchain-technology-big-platform-300571305.html
Chart>>>>
http://stockcharts.com/h-sc/ui?s=SRAX&p=D&yr=1&mn=0&dy=0&id=p14017775238
I feel blockchain is coming, but bitcoin,. etc. will be replace by a government crypto currency. Bitcoin = Tulips IMO.
U.S. Lithium Mining Could Get a Boost From President Trump's Executive Order
https://www.fool.com/investing/2018/03/09/us-lithium-mining-could-get-a-boost-from-president.aspx
In late December, President Donald Trump signed an executive order directing the relevant federal agencies to develop a strategy to reduce the United States' reliance on foreign sources of "critical minerals" that are used to make products deemed essential to our country's economic and national security. Lithium was named as one such mineral, as it's crucial for producing the lithium-ion batteries that power electric vehicles (EVs), consumer electronic gadgets, and energy-storage products.
Investors should be aware of this under-reported move since it could have ramifications in the lithium space, which has been white-hot since 2016, though lithium stocks have pulled back in 2018.
It's too soon to say which lithium companies could benefit, though possibilities include the world's largest lithium producer, North Carolina-based Albemarle (NYSE:ALB), which has a lithium mining operation in this country, and one or more of the junior miners, such as Lithium Americas (NYSE:LAC), that are exploring the viability of mining lithium in the U.S.
Here's what you should know.
"A Federal Strategy to Ensure Secure and Reliable Supplies of Critical Minerals"
The Republican president's executive order No. 13817 aims to encourage domestic production of critical minerals in order to reduce our country's reliance on foreign sources, which "creates a strategic vulnerability" for both our "economy and military to adverse foreign government action, natural disaster, and other events that can disrupt supply of these key minerals." The impetus for the directive was a report by the U.S. Geological Survey that concludes that foreign sources provide at least 50% of our total needs for 21 out of 23 critical minerals, including lithium. Moreover, it spells out just how dependent we are on the Chinese to supply many of these minerals.
Nobody on either side of the political aisle would likely argue with the worthiness of the goal of the executive order, but there will surely be big differences of opinions on how to achieve it. We can't know for sure what tact the Trump administration will want to take, though some political observers believe it could want to weaken environmental regulations in the name of "streamlining leasing and permitting processes as to expedite exploration, production, processing, reprocessing, recycling, and domestic refining of critical minerals."
The current domestic lithium production picture
There's just one active commercial lithium mine in North America: a brine mine in Silver Peak, Nevada, which is owned and operated by Albemarle and was the first lithium brine mining operation in the world. (Albemarle also has two other sources of lithium -- Salar de Atacama, Chile, where lithium is extracted from brine, and its Talison Lithium joint venture with China's Tiangi Lithium in Australia, which is an an open-pit, hard-rock mining operation.) The U.S., which once controlled the lithium mining industry, produced just 3% of the world's lithium supply in 2015, according to Deutsche Bank, with Chile (37%), Australia (33%), Argentina (11%), and China (10%) dominating lithium production.
Parts of Chile and Argentina, along with Bolivia, form the "Lithium Triangle," a region that supplies the bulk of the world's lithium that comes from brine and contains about 54% of the world's total known lithium reserves. Australia reigns supreme in mining lithium from hard rock, or spodumene, which it ships to China for processing. Obtaining lithium from underground brine has proven to be a cheaper process than obtaining it from hard rock, which is why the U.S.'s hard-rock lithium mining industry centered in North Carolina dried up once the South American countries started tapping their immense underground lithium reserves to take advantage of the growing market for lithium. These countries, particularly Chile, have an inherent advantage in that their brine is extremely mineral-rich and their scorching desert climates and high altitudes provide an ideal environment for the solar evaporation process involved in extracting lithium from brine. This is a big reason Sociedad Química y Minera de Chile (NYSE:SQM), or SQM, the world's second-largest producer of lithium that obtains 100% of its lithium from the Atacama salt flat, is the world's lowest-cost producer of lithium.
The surge in the price of lithium over the last few years has spurred a "white-gold rush," with many junior miners in various stages of exploring the viability of mining lithium in the U.S. A good number of claims have been staked near Albemarle's Nevada brine operation, while other companies are focused on California (geothermal brine), North Carolina (hard-rock mining), Utah (oil field brine in the Paradox Basin), and Arkansas (oil field brine). Notable among these are Lithium Americas, which is exploring a new technology to extract lithium from hectorite clay at its Lithium Nevada project. The company also has a 50-50 joint venture with SQM on the Cauchari-Olaroz lithium brine project in Argentina, with production expected to begin in 2020.
Investor takeaway
We don't know how the Trump administration will go about achieving its aim of reducing the U.S.'s reliance on foreign sources of critical minerals, so it's too soon to opine about the best investment angle. The only way the U.S. has even a shot at being competitive in producing lithium, in my opinion, is by providing incentives for companies operating in the country to develop new and as-clean-as-possible technologies that are more efficient than what's now available at extracting lithium from brine, hard rock, or clay, with brine and clay likely being the best bets.
The move away from oil is real?>>>>>
Plans Unveiled for World's Largest, Most Powerful Offshore Wind Turbine
https://www.ecowatch.com/offshore-wind-turbine-ge-2541368284.html
GE Renewable Energy has unveiled plans to develop the world's largest and most powerful offshore wind turbine.
Each 12-megawatt Haliade-X stands 853 feet tall, or roughly five times the height of the Arc de Triomphe in Paris, and features 350-foot blades, or the length of a Major League Soccer field.
One turbine can generate 67 gigawatt-hours annually, or enough clean energy for up to 16,000 households. A 750-megawatt wind farm configuration could power 1 million households. GE says the Haliade-X will produce 45 percent more energy than any other offshore wind turbine available today.
"We want to lead in the technologies that are driving the global energy transition," General Electric CEO John Flannery said.
Companies are making bigger and bigger offshore turbines that can capture more wind and produce more power. This is appealing for wind farm developers because fewer turbines can simplify operations and lower maintenance costs.
Greentech Media pointed out that GE is "playing catchup" with its competitors. Its current 6-megawatt offshore turbines, which are installed at the Block Island Wind Farm off Rhode Island, lags behind the ones made by MHI Vestas and Siemens Gamesa Renewable Energy.
GE estimates the new turbine will achieve a 63 percent capacity factor, which is five to seven points more than the industry benchmark, noting that each percentage point in capacity factor is worth around $7 million.
More than $400 million will be invested over the next three to five years to develop the Haliade-X. The company aims to supply its first nacelle, or power generating unit, for demonstration in 2019 and ship the first units in 2021.
"The renewables industry took more than 20 years to install the first 17 GW of offshore wind. Today, the industry forecasts that it will install more than 90 GW over the next 12 years," said Jérôme Pécresse, president and CEO of GE Renewable Energy. "This is being driven by lower cost of electricity from scale and technology. The Haliade-X shows GE's commitment to the offshore wind segment and will set a new benchmark for cost of electricity, thus driving more offshore growth."
$90 Billion In Investments Into EVs & Batteries Now Pledged By Global Auto Manufacturers
http://lithium-news.com/2017/12/03/lithium-juniors-could-rally-following-teslas-interest-in-argentina/
That tune has almost 8m plays. They must be making money. I never hear of them til last night. I search a new alternative radio station in Minneapolis for new stuff. and saw it.
http://onlineradiobox.com/us/ktwn/playlist/6?cs=us.ktwn
Thanks, I like them guys. Wish i had there money!
SQM talks down lithium oversupply, says market to grow 80% a year
http://www.mining.com/sqm-talks-lithium-oversupply-says-market-grow-80-year/?utm_source=digest-en-mining-180301&utm_medium=email&utm_campaign=digest
We can't always look at the past for future guidance. Things change.
A while back I checked out a group of big and medium food stocks in the March 2000 - October 2002 bear market. In that market, the internet laden NASDAQ lost 66% of it's value, S & P half that. The food stocks I checked, such as GIS, ADM, CALM, MED, etc had a gain of 2 and 1/2 % in that time period plus dividends, less brokerage fees.
This time, no way does that happend if we are in a bear.. Expanded PE's in many of the foods are outrageous now. Kellogg PE 19, Bunge 86, Nestle 33, NTRI 23, COST 30, etc.
This time I am betting on food commodities through RJA. Gold has always scared me with all the manipulation, but yes, it could soar as well as sliver. RJA has a nice gradual chart going for it. Spikes in food commodities and not good buys,
http://stockcharts.com/h-sc/ui?s=RJA&p=D&yr=1&mn=0&dy=0&id=p49560099375
Article by a commodities trader on spikes >>>>
http://seeryfutures.com/content/you-must-understand-chart-structure-2#.Wo4EdBISDTI.twitter
You Must Understand Chart Structure
What do I mean when I talk about chart structure and why do I think it’s so important when deciding to enter or exit a trade? I define chart structure as a slow grinding up or down trend with low volatility and no chart gaps. Many of the great trends that develop have very good chart structure with many low percentage daily moves over a course of at least 4 weeks thus allowing you to enter a market allowing you to place a stop loss relatively close due to small moves thus reducing risk.
Charts that have violent up and down swings are not considered to have solid chart structure as I like to place my stops at 10 day highs or 10 day lows and if the charts have a tight pattern that will allow the trader to minimize risk which is what trading is all about and if the chart has big swings your stop will be further away allowing the possibility of larger monetary loss.
Good charts by that definition?
http://stockcharts.com/h-sc/ui?s=JJG&p=D&yr=1&mn=0&dy=0&id=p62153357393
http://stockcharts.com/h-sc/ui?s=RJA&p=D&yr=1&mn=0&dy=0&id=p49560099375
http://stockcharts.com/h-sc/ui?s=CORN&p=D&yr=1&mn=0&dy=0&id=p51278931461
Here is a speculation one I am watching, even though I think sugar is evil
http://stockcharts.com/h-sc/ui?s=SGG&p=D&yr=3&mn=0&dy=0&id=p53113225485
I am the worlds foremost expert in one area, nothing else and that is MY OPINION--beware!
Been quiet everywhere except for a few hot stocks. Getting bored, lol, but still not bullish.Yep fitz, have a nice weekend.
Thanks wow, Have a nice weekend!
$LQMT, wake up call?
http://stockcharts.com/h-sc/ui?s=LQMT&p=D&yr=1&mn=0&dy=0&id=p54547031422
$RENN Shaping up, I am buying nothing, looking for a good exit on RIBT, still holding RJA for the long haul. I post RENN in case anybody else is interested. The market scares the H out of me, boo. Which may mean, BUY, lol.
http://stockcharts.com/h-sc/ui?s=RENN&p=D&yr=1&mn=0&dy=0&id=p20454466972
$ADVM so early #CRISPR
http://stockcharts.com/h-sc/ui?s=ADVM&p=D&yr=1&mn=0&dy=0&id=p11554435425
$PVCT,
Newspaper Article Reports Clinical Trial Subject's Experience with PV-10
Thursday February 22, 2017
On February 16, 2018, an article was published in the Adelaide, Australia newspaper The Advertiser describing the experiences of the two patients participating in the Provectus-sponsored clinical trial, "A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumors Metastatic to the Liver" (NCT02693067).
The video article is available from The Advertiser website at:
http://www.adelaidenow.com.au/news/south-australia/cancer-drug-rose-bengal-lets-michael-button-walk-daughter-down-the-aisle/news-story/98f49f66a47d733130a20efadae15e29
Cancer drug Rose Bengal lets Michael Button walk daughter down the aisle
Why The Next Oil Boom Will Be Fueled By Blockchain
Maybe this old geezer should read up on blockchain, lol. I know nothing about it, boo.
https://oilprice.com/Energy/Energy-General/Why-The-Next-Oil-Boom-Will-Be-Fueled-By-Blockchain.html
Big Oil is due for a disruption.
The world’s most important industry has been carrying on without any significant changes in its day to day routine for far too long.
But now, the new tech on the block has its sights set on the multi-trillion-dollar oil and gas sector.
It’s official: Blockchain technology has infiltrated Big Oil.
The hype behind blockchain has reached a full-blown frenzy. And for good reason.
The technology, which creates secure ledgers for digital transactions and rapidly accelerates the pace at which transactions can be made, has the potential to disrupt every major industry: real estate, shipping, banking and healthcare.
Blockchain is truly revolutionary, and Big Oil is finally catching on.
In an industry that has used technology to reduce breakeven costs to all-time lows, create gigantic drilling rigs run by robots, and even tap reserves located 10 miles below the sea, the oil and gas sector has been slow to jump on the blockchain bandwagon…until now.
According to a report from the World Economic Forum from 2017, a digital transformation has already swept across the energy industry.
Now, blockchain is taking it one step further.
Majors like BP and Shell are making headlines with plans to utilize blockchain tech to completely transform how energy is bought and sold.
Smaller players with big ambitions like Canada’s Petroteq are preparing to revolutionize the day to day operations of potentially every oil operation on the planet. Petroteq could utilize new technologies to tap massive new reserves of energy, such as the Utah oil sands, while radically reducing environmental risk.
With U.S. President Donald Trump planning a trillion dollar infrastructure program, the possibilities for upgrading American oil and gas systems throughout the country are immense.
Integrating blockchain into supply-line management and logistics could dramatically cut costs.
Major Innovation
The oil majors are waking up to blockchain possibilities.
BP began experimenting with blockchain technology in 2017. David Eyton, BP’s head of technology, noted: “There are uses for blockchain that could give us a competitive advantage.”
In BP’s pilot program, the company began working with Italian supermajor Eni, and Austria’s Wien Energie on a trading platform using blockchain technology.
And in November, BP joined a blockchain consortium with fellow industry heavyweights Shell and Statoil, in addition to commodity trading houses – Gunvor, Koch Supply & Trading, and Mercuria, with the financial backing of Dutch ABN Amro, ING, and French Societe Generale.
Patrick Arnaud, Managing Director for Trade & Commodity Finance, ING, said: “The commodity finance industry is hampered by nature by inefficiencies and outdated procedures. By applying blockchain technology, we expect that we can eliminate a lot of these, making the overall process faster and more cost effective.”
Royal Dutch/Shell is taking it a step further, investing in a minority stake in the distributed ledger startup Applied Blockchain. The blockchain firm has created platforms across a range of sectors including telecom, manufacturing, and more.’
Petroteq and the Blockchain
While the supermajors are focused on trading, others are looking to the tech for far more creative endeavors.
Petroteq (OTC: PQEFF; TSX-V: PQE), a company that made waves in the sector with its revolutionary patented oil sands tech, has set out on a mission to completely overhaul the industry’s inefficient and error prone supply chain management protocols.
Petroteq was recently cited by Geoffrey Cann, a Director at Deloitte specializing in the oil and gas industry, as a contender for blockchain technologies in the energy arena.
Oil and gas is a global endeavor in which huge inventories are held, ordered, transported, and distributed through multiple channels all over the globe. When things go wrong, productivity is slowed, production levels fall, and cargo is lost. This means billions in profit is potentially taken off the table.
And with the development of new energy sources such as shale gas, tight oil, oil sands, and coal seam gas reaching a critical mass, it’s more important now than ever to rethink traditional supply chains.
This is the path on which Petroteq has embarked. And with the help of blockchain technology, the company is positioning itself as a leader in this race.
Petrobloq, Petroteq’s very own blockchain consortium, is looking to reshape the industry. From drilling, to a finished petroleum-based product and everywhere in between, Petrobloq aims to track, monitor, and account for every drop of petroleum on a transparent, immutable, and secure blockchain.
The first member of the Petrobloq consortium is Latin America’s second largest energy company, PEMEX, which made headlines as the first petroleum company to allow cryptocurrency as a payment option in participating gas stations. In joining the consortium, the company looks to soar to new heights.
Utilizing Petroteq’s technology, Mexico’s national oil company will become one of the world’s largest non-publicly traded companies to introduce a blockchain-based supply chain management platform. An endeavor which is set to bring PEMEX’s processes from production to sale to an entirely new level, ushering in a new era of efficiency and profitability.
These heavy hitting partnerships will certainly disrupt the entire industry. Data will be shared seamlessly between joint ventures. The time it takes to cut a deal will be reduced significantly. And perhaps most importantly, the middle man essentially disappears, reducing costs for every sub-section of the industry.
American Energy Dominance
The dramatic improvements planned for U.S. infrastructure will incorporate innovations from companies like Petroteq.
President Trump announced a $1.5 trillion infrastructure plan at the State of the Union Address in January. That means billions will be invested into dilapidated oil and gas infrastructure.
The Trump Administration has made energy dominance a high priority. The Utah oil sands will play a huge part in advancing the future of American energy.
And Petroteq has technology to unlock the full potential of the Utah fields and their 32 billion barrels of oil.
And unlike the dirty, expensive tar sands of Canada, Petroteq will be able to exploit the Utah oil sands in an environmentally-friendly, cost-effective way through their proprietary technology.
Once the fields of Utah are on-line, U.S. imports of oil from overseas, which are already in decline, could end altogether. The importance of Utah oil sands will push demand for it up and up, making it some of the most valuable oil on the market.
With its mastery of blockchain, Petroteq will be at the head of the pack. But its innovative drive forward is sure to be matched by other companies in the oil and gas sector.
In such a globally connected economy, the impact of transitioning to blockchain tech will be profound and will likely turn any industry on its head.
From oil majors like BP and Shell, to smaller innovators like Petroteq, massive potential is set to be unlocked in the oil and gas industry through the innovative use of new technology.
Oil and gas companies using tech to change the industry:
British Petroleum (NYSE:BP) is a multi-national oil and gas supermajor, and the sixth largest energy company on the planet. The company is over 100 years old and is not afraid of reinventing the wheel. And that’s exactly what they’re doing.
As blockchain forced its way into nearly every industry, BP took note. In October 2017, BP begun experimenting with a blockchain-based oil trading platform, with the goal of implementing “practical and ethical” uses of the technology.
With BP’s forward-thinking mindset and vast amount of resources and assets, the company is always looking to learn about and adopt new technology.
Royal Dutch Shell (NYSE:RDS.A) is household name. As one of the largest energy companies on the planet, Shell knows the industry through and through. Shell also has its eyes on the blockchain industry. The company is no stranger to technology, and sees blockchain’s clear benefits, and looks to become an early adopter within the industry.
With BP, Shell is leading a blockchain movement within the industry that is set to revolutionize the way oil and gas is bought and sold. Their platform is set to be launched by the end of 2018, and investors are clearly on the edge of their seats in anticipation.
Pengrowth Energy Corp. (TSX:PGF, NYSE:PGH): Another company that looks to have halted its falling stock price and is now preparing to ride the bullish sentiment in oil markets. Having shed a lot of excess weight this year in massive asset selloffs, investors can expect a much leaner and meaner Pengrowth in 2018.
For those investors who like to follow the smart money, billionaire investor Seymour Schulich bought millions of extra shares in Pengrowth in early October, boosting his position from 19 percent of the stock to 24 percent. He claims that he is confident that oil and gas is going up.
Pembina Pipeline Corp. (TSE:PPL, NYSE:PBA): The North American pipeline industry has had a tough year, but the recent approval of the Keystone XL pipeline route and the growing need for transportation capacity should act as a boon for the sector.
Pembina Pipeline Corp. has ridden the oil price crash in an impressive manner, maintaining a good stock price and increasing its dividend. This is a stock that pays you to wait, and as the sector continues to improve it is likely investors will see good gains here.
TransCanada (TSX:TRP, NYSE:TRP): is a major oil and energy company based in Calgary, Canada. The company owns and operates energy infrastructure throughout North America. TransCanada is one of the continent’s largest providers of gas storage, and owns and has interests in approximately 11,800 megawatts of power generations.
With TransCanada’s massive influence throughout North America, it is no wonder that the company is among one of Canada’s highest valued energy companies. Investors can feel comfortable with the company due to its huge and diverse portfolio, and continuing eye for success.
$PVCT news,
Provectus Biopharmaceuticals Provides Update on GI Cancer Program for Investigational Drug PV-10
Thursday February 22, 2018
- Current Phase 1 basket study continues to enroll and treat patients for HCC and liver cancer metastases (colorectal, lung, pancreatic, melanoma, ovarian, and breast); updated data presentation planned for 2018 -
- First expansion of GI cancer program, Phase 1 study of PV-10 for symptomatic NET metastatic to liver, has now treated multiple patients; preliminary data presentation planned for 2018 -
- Projected second program expansion: Phase 1b/2 study of PV-10 neoadjuvant to chemotherapy for metastatic pancreatic cancer -
KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing the first small molecule oncolytic immunotherapy for solid tumor cancers, today provided an update on the Company's gastrointestinal ("GI") cancer clinical development program for its lead investigational drug PV-10, which is administered percutaneously when targeting GI cancer tumors.
Provectus' Phase 1 study of patients with hepatic lesions (a "basket study" open to patients with different hepatic tumor types and entitled A Study to Assess PV-10 Chemoablation of Cancer of the Liver, NCT00986661) has treated 18 patients at four U.S. sites to date: six patients with hepatocellular carcinoma ("HCC"), six patients with metastatic colorectal cancer ("mCRC") metastatic to the liver, and six patients with breast cancer, lung cancer, melanoma, ovarian cancer or pancreatic cancer liver metastases. A fifth U.S. site is currently projected to enroll patients in the first half of 2018 and focus on uveal melanoma metastatic to the liver.
The most recent data from this basket study was presented at the 9th Annual Symposium of Clinical Interventional Oncology ("CIO") in Hollywood, Florida on February 4-5, 2017 (a similar presentation was made at the 26th Conference of the Asian Pacific Association for the Study of the Liver in Shanghai, China on February 15-19, 2017). Results included:
Two of six patients with HCC who remained alive for 58 and 75 months after treatment, the latter with no evidence of disease;
Four of five patients with mCRC liver metastases who remained alive 9 to 73 months after treatment, including one patient with no evidence of disease at 73 months; and
One patient with pancreatic cancer liver metastases who remained alive 12 months after treatment.
Evidence of tumor destruction in both target (injected) and bystander (non-injected) lesions was displayed. A copy of the CIO poster presentation is available on Provectus' website. Provectus currently plans to present updated data from this basket study at a medical conference in the second half of 2018.
In February 2017, researchers at the University of Illinois at Chicago published work elucidating PV-10's mechanism of action in colon cancer, whereby PV-10 may induce immunogenic cell death that contributes to specific antitumor immunity.1
In April 2017, the first patient was treated in the Company's first expansion trial of the GI cancer program (A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumors Metastatic to the Liver, NCT02693067). The patient, who had multifocal disease refractory to Lutate (177Lu-DOTA-octreotate, a radio-labelled somatostatin analog; also known as LUTATHERA®, which was approved earlier this month by the U.S. Food and Drug Administration), received percutaneous PV-10 to a single neuroendocrine tumor ("NET") metastasis, and subsequently received a second injection of PV-10 to a second NET metastasis.2 Since then, a second patient received a first injection.2 Provectus currently plans to present preliminary data from this study at a medical conference in the second half of 2018.
Provectus is planning to initiate a second expansion of its GI cancer program focused on metastatic pancreatic cancer. This new study will be the first clinical combination use of PV-10 in GI cancer:
The study, with the preliminary title A Phase 1b/2 study of percutaneous PV-10 neoadjuvant to chemotherapy for metastatic pancreatic cancer, builds on the data from the Company's hepatic basket and NET trials to address pancreatic cancer that has metastasized to the liver. Prior preclinical work by Moffitt Cancer Center established that PV-10 has therapeutic activity in pancreatic cancer murine models as both a single agent and in combination with gemcitabine, a standard chemotherapeutic agent used to treat this disease.3
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "GI cancers as a group are responsible for more deaths than any other disease type. Provectus and its research collaborators have independently established PV-10 as an oncolytic immunotherapy in melanoma4, colon cancer, and pancreatic cancer. We will expand our GI cancer clinical development program by continuing to initiate trials where PV-10, either as a single agent or in combination with another class of agent, may address multiple different indications with substantial unmet need or that are rare diseases."
About Provectus
Provectus is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Intralesional PV-10, the first small molecule oncolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers like melanoma and cancers of the liver as well as preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses like psoriasis; pathways significantly improved by PH-10 treatment include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22 and interferons. Information about the Company's clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "would," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016).
References:
1. Qin J., Kunda N., Qiao G., Calata J.F., Pardiwala K., Prabhakar B.S., Maker A.V. (2017), Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017 Feb 2;8(2):e2584. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386459/.
2. On February 16, 2018, an article was published in the Adelaide, Australia newspaper The Advertiser describing the experiences of the two patients participating in the Phase 1 NET study. DISCLAIMER: In linking to the article Provectus makes no claims about the safety or efficacy of investigational drug PV-10.
3. Pilon-Thomas S., Weber A., Morse J., Kodumudi, K., Liu H., Mullinax J., Sarnaik A.A., (2016), Intralesional injection with Rose Bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer. Journal for ImmunoTherapy of Cancer 2016 4(Suppl 1):73. https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0173-6.
4. Liu H., Innamarato P.P., Kodumudi K., Weber A., Nemoto S., Robinson J.L., Crago G., McCardle T., Royster E., Sarnaik A.A., Pilon-Thomas S. (2016), Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget, 7:37893–37905. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122358/.
Trademark:
LUTATHERA® is a registered trademark of Advanced Accelerator Applications S.A., Saint-Genis-Pouilly, France.
Contact:
Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.
President
Phone: 866-594-5999
Southern Copper wins auction for massive Peru copper project
http://www.mining.com/rio-teck-hudbay-among-bidders-massive-peru-copper-project/?utm_source=digest-en-mining-180220&utm_medium=email&utm_campaign=digest
Copper, iron ore price jump sparks rally in mining stocks
http://www.mining.com/copper-iron-ore-price-jump-sparks-rally-mining-stocks/?utm_source=digest-en-mining-180214&utm_medium=email&utm_campaign=digest
Hey buddy, what is your thoughts on $ONCI?
Rio Tinto back in race for stake in world’s largest lithium miner
http://www.mining.com/rio-tinto-back-race-stake-worlds-largest-lithium-miner/?utm_source=digest-en-mining-180202&utm_medium=email&utm_campaign=digest
Yep, you and I are not surprised. The Dow can fall 30% and still be higher than election day 2016,
Dow industrial heads for biggest weekly point setback in 9 years, weekly drop of 1,100
https://www.marketwatch.com/story/the-dow-industrials-have-tumbled-730-points-this-week-its-worst-point-loss-in-2-years-2018-02-02
Goldman all but says the mining supercycle is back
http://www.mining.com/goldman-says-mining-supercycle-back/?utm_source=digest-en-mining-180201&utm_medium=email&utm_campaign=digest
I am not trading, lol. Just holding RJA and RIBT,. looking for an exit on RIBT.
I put up a lot of posts today about the expanding drought in the West and South especially.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138187696
http://droughtmonitor.unl.edu/Maps/CompareTwoWeeks.aspx
Then I sent them to Andrew Hecht who writes about commodities for Seeking Alpha and to Mike Seery who is President of Seery Futures A Commodity Consulting Firm helping traders become educated.He have appeared on Fox, CNBC, Bloomberg Business Channels.
Low and behold Bob Hensen puts out an article on his Weather Underground at 3:45 E. I wonder if one of the two sent them mine and asked for an opinion. RJA went from down to up on the day, God am I great or whet, lol. In reality, neither of the guys I sent it to probably never red it, lol.
https://www.wunderground.com/cat6/california-and-beyond-states-expanding-drought
How you doing buddy? I have been really busy fixing and selling cars.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |